RTW Investments’s MoonLake Immunotherapeutics MLTX Stock Holding History

RTW Investments’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-741,090	Closed	-$35M	–	79
2025 Q2	$35M	Buy	+741,090	New	+$30.2M	0.5%	42
2023 Q4	–	Sell	-500,000	Closed	-$28.5M	–	68
2023 Q3	$28.5M	Hold	500,000	–	–	0.6%	32
2023 Q2	$25.5M	Hold	500,000	–	–	0.49%	35
2023 Q1	$10.7M	Hold	500,000	–	–	0.22%	42
2022 Q4	$5.25M	Hold	500,000	–	–	0.11%	58
2022 Q3	$3.88M	Hold	500,000	–	–	0.09%	72
2022 Q2	$2.63M	Buy	+500,000	New	+$3.14M	0.07%	94
2021 Q4	–	Sell	-750,000	Closed	-$7.39M	–	129
2021 Q3	$7.39M	Hold	750,000	–	–	0.11%	84
2021 Q2	$7.76M	Hold	750,000	–	–	0.12%	80
2021 Q1	$7.66M	Hold	750,000	–	–	0.12%	79
2020 Q4	$8.53M	Buy	+750,000	New	+$7.96M	0.14%	72

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

RTW Investments's MLTX Position: Q3 2025 in Review

RTW Investments sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2025, closing a stake of 741,090 shares — an estimated $35M sold.

RTW Investments first reported a position in MLTX in Q4 2020 and held it in 11 quarters. The position peaked at $35M in Q2 2025. 134 funds tracked by Wall St. Rank hold MLTX as of Q3 2025.

RTW Investments reported no remaining MoonLake Immunotherapeutics position as of Q3 2025 after selling out during the quarter.
RTW Investments sold 741,090 MoonLake Immunotherapeutics shares in Q3 2025, an estimated $35M.
RTW Investments first reported a position in MoonLake Immunotherapeutics in Q4 2020 and held it in 11 quarters.
RTW Investments's MoonLake Immunotherapeutics position peaked at $35M in Q2 2025.
134 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2025.

Based on RTW Investments's 13F filing for Q3 2025, filed 14 Nov 2025.